Robert A. Lippe Joins Alexza Pharmaceuticals as Executive Vice President, Operations and Chief Operations Officer

  Robert A. Lippe Joins Alexza Pharmaceuticals as Executive Vice President,
                   Operations and Chief Operations Officer

PR Newswire

MOUNTAIN VIEW, Calif., Feb. 25, 2014

MOUNTAIN VIEW, Calif., Feb. 25, 2014 /PRNewswire/ -- Alexza Pharmaceuticals,
Inc. (Nasdaq: ALXA) announced today that Robert A. Lippe has joined the
Company as Executive Vice President, Operations and Chief Operations Officer.
In this newly created position, Mr. Lippe has responsibility for the Company's
global operation functions, including strategic development and execution of
clinical and commercial manufacturing, quality and compliance, supply chain
and supply partner management, technology transfer, facilities, sustainment
engineering and IT in support of the Company's product and technology


"With the ongoing commercialization of ADASUVE in the U.S. and EU, and
commercial partnerships in place with Teva and Ferrer, it is an exciting time
to join Alexza," said Mr. Lippe. "I look forward to working with Alexza's
talented team to develop world-class operational capability and continued
organizational success in bringing innovative products to patients."

"We are pleased to welcome Rob to our senior management team," said Thomas B.
King, President and CEO. "Rob brings an extensive set of operational skills,
along with a strategic sense and outlook. We look forward to his
contributions as we continue the growth of the Company through the global
launch of ADASUVE and expansion of our product candidate pipeline."

Mr. Lippe brings more than two decades of experience in operations with
multinational biopharmaceutical companies and national research laboratories.
From January 2011 to February 2014, Mr. Lippe served as the Head of Global
Operations & Operational Excellence at Ironwood Pharmaceuticals, Inc. Prior
to Ironwood, Mr. Lippe worked for Genentech, Inc. from 2002 to 2011. From
October 2007 to January 2011, Mr. Lippe served as the Head of Manufacturing
for Genentech's Vacaville Operations. From May 2002 until October 2007, Mr.
Lippe held multiple positions in strategic operations, drug substance and drug
product manufacturing, and facilities. Prior to joining Genentech, Mr. Lippe
spent ten years at Lawrence Livermore National Laboratory and six years as an
officer in the U.S. Coast Guard. Mr. Lippe received his MPH and MBA degrees
from the University of California, Berkeley, and received a BS degree in
marine engineering from the United States Coast Guard Academy.

About Alexza Pharmaceuticals, Inc.
Alexza Pharmaceuticals is focused on the research, development and
commercialization of novel, proprietary products for the acute treatment of
central nervous system conditions. Alexza's products are based on the
Staccato^® system, a hand-held inhaler designed to deliver a drug aerosol to
the deep lung, providing rapid systemic delivery and therapeutic onset, in a
simple, non-invasive manner.

ADASUVE^® (Staccato loxapine) is Alexza's first commercial product, which was
approved by the U.S. Food and Drug Administration in December 2012 and by the
European Commission in February 2013. Teva Pharmaceuticals USA, Inc. is
Alexza's commercial partner for ADASUVE in the U.S. Grupo Ferrer
Internacional, S.A. is Alexza's commercial partner for ADASUVE in Europe,
Latin America, Russia and the Commonwealth of Independent States countries.

ADASUVE^® and Staccato^® are registered trademarks of Alexza Pharmaceuticals,

Safe Harbor Statement
This news release contains forward-looking statements that involve significant
risks and uncertainties. Any statement describing the Company's expectations
or beliefs is a forward-looking statement, as defined in the Private
Securities Litigation Reform Act of 1995, and should be considered an at-risk
statement. Such statements are subject to certain risks and uncertainties,
particularly those inherent in the process of developing and commercializing
drugs, including the ability of Alexza and our partners, Teva and Ferrer, to
effectively and profitably commercialize ADASUVE, estimated product revenues
and royalties associated with the sale of ADASUVE, the adequacy of the
Company's capital to support the Company's operations, and the Company's
ability to raise additional funds and the potential terms of such potential
financings. The Company's forward-looking statements also involve assumptions
that, if they prove incorrect, would cause its results to differ materially
from those expressed or implied by such forward-looking statements. These and
other risks concerning Alexza's business are described in additional detail in
the Company's Annual Report on Form 10-K for the year ended December 31, 2012
and the Company's other Periodic and Current Reports filed with the Securities
and Exchange Commission. Forward-looking statements contained in this
announcement are made as of this date, and the Company undertakes no
obligation to publicly update any forward-looking statement, whether as a
result of new information, future events or otherwise.

SOURCE Alexza Pharmaceuticals, Inc.

Contact: BCC Partners, Karen L. Bergman, 650.575.1509,, or Michelle Corral, 415.794.8662,
Press spacebar to pause and continue. Press esc to stop.